A well-connected company with close ties to a key Obama Administration official may be running afoul of the SEC by failing to report to its investors material events that significantly impact its bottom line. Just another day in Barack Obama’s Washington, DC “favor factory.”

Capital Confidential has in the past covered the saga of PharmAthene, a company that produces “medical countermeasures to biological and chemical weapons” and its great fortune to have been awarded the sole-source contract from the Biomedical Advanced Research and Development Authority (BARDA).

Read the rest at Big Government